Genomic Valley Biotech Ltd
GVBLGenomic Valley Biotech Ltd
GVBL
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 121.01 | 8.94 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Genomic Valley Biotech Ltd is conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market
Peers
Compare with peersBiocon Ltd
Hester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.27 | 0.52 | 0.62 | 1.00 | 0.86 | 0.21 | 0.57 | 2.76 | 0.17 | 0.41 | ||||||||||
Raw Materials | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.58 | 0.15 | 0.15 | ||||||||||
| Power & Fuel Cost | 0.04 | 0.01 | 0.01 | 0.05 | 0.02 | 0.00 | 0.01 | 0.00 | ||||||||||||
| Employee Cost | 0.13 | 0.25 | 0.34 | 0.27 | 0.18 | 0.09 | 0.14 | 0.15 | ||||||||||||
| Selling & Administrative Expenses | 0.25 | 0.10 | 0.09 | 0.14 | 0.09 | 0.08 | 0.13 | 0.09 | ||||||||||||
| Operating & Other expenses | 0.06 | 0.18 | 0.05 | 0.11 | -0.00 | 0.18 | 0.17 | 0.28 | ||||||||||||
EBITDA | -0.28 | -0.02 | 0.13 | 0.43 | 0.57 | -0.14 | 0.12 | 0.66 | 0.02 | 0.26 | ||||||||||
| Depreciation/Amortization | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | — | ||||||||||
| PBIT | -0.33 | -0.06 | 0.05 | 0.24 | 0.39 | -0.33 | 0.04 | 0.65 | 0.02 | 0.26 | ||||||||||
| Interest & Other Items | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | — | ||||||||||
| PBT | -0.35 | -0.06 | 0.05 | 0.24 | 0.21 | -0.51 | 0.00 | 0.65 | 0.02 | 0.26 | ||||||||||
| Taxes & Other Items | -0.01 | 0.00 | 0.02 | 0.00 | -0.08 | 0.06 | 0.01 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -0.34 | -0.06 | 0.03 | 0.24 | 0.29 | -0.57 | -0.01 | 0.65 | 0.02 | 0.26 | ||||||||||
| EPS | -1.11 | -0.20 | 0.10 | 0.79 | 0.95 | -1.87 | -0.03 | 2.13 | 0.05 | 0.85 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Genomic Valley Biotech Ltd | 1,573.07 | 8.94 | — |
| Biocon Ltd | 37.63 | 1.52 | 0.16% |
| Hester Biosciences Ltd | 120.45 | 7.51 | 0.22% |
| Panacea Biotec Ltd | -1,871.55 | 2.59 | — |
Price Comparison
Compare GVBL with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 9.53%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 10.92%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
GVBL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Genomic Valley Biotech rose 650.00% to Rs 0.15 crore in the quarter ended September 2024 as against Rs 0.02 crore during the previous quarter ended September 2023. Sales rose 200.00% to Rs 0.21 crore in the quarter ended September 2024 as against Rs 0.07 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.210.07 200 OPM %66.6728.57 - PBDT0.150.02 650 PBT0.150.02 650 NP0.150.02 650 Powered by Capital Market - Live
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 7 October 2024.Powered by Capital Market - Live
Genomic Valley Biotech standalone net profit rises 333.33% in the June 2024 quarter
Net profit of Genomic Valley Biotech rose 333.33% to Rs 0.13 crore in the quarter ended June 2024 as against Rs 0.03 crore during the previous quarter ended June 2023. Sales rose 166.67% to Rs 0.16 crore in the quarter ended June 2024 as against Rs 0.06 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.160.06 167 OPM %81.2550.00 - PBDT0.130.03 333 PBT0.130.03 333 NP0.130.03 333 Powered by Capital Market - Live
Genomic Valley Biotech will hold a meeting of the Board of Directors of the Company on 29 July 2024.Powered by Capital Market - Live
Genomic Valley Biotech reports standalone net profit of Rs 0.06 crore in the September 2022 quarter
Genomic Valley Biotech reports standalone net profit of Rs 0.01 crore in the December 2021 quarter
Genomic Valley Biotech reports standalone net loss of Rs 0.11 crore in the June 2021 quarter
Genomic Valley Biotech reports standalone net loss of Rs 0.38 crore in the March 2021 quarter
Genomic Valley Biotech reports standalone net loss of Rs 0.01 crore in the December 2020 quarter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -29.84%, vs industry avg of 19.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.01% to 0%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -39.16%, vs industry avg of 1.42%